Insider Trading Alert - IRMD, PMCS And EXAM Traded By Insiders

Yesterday, Dec. 10, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $42,564,049.20.

Highlighted Stocks Traded by Insiders:

iRadimed (IRMD) - FREE Research Report

Nardi Steven M., who is VP of Manufacturing at iRadimed, sold 500 shares at $30.99 on Dec. 10, 2015. Following this transaction, the VP of Manufacturing owned 100 shares meaning that the stake was reduced by 83.33% with the 500-share transaction.

The shares most recently traded at $29.26, down $1.73, or 5.92% since the insider transaction. Historical insider transactions for iRadimed go as follows:

  • 4-Week # shares sold: 3,960
  • 12-Week # shares sold: 3,960
  • 24-Week # shares sold: 10,810

The average volume for iRadimed has been 66,800 shares per day over the past 30 days. iRadimed has a market cap of $330.8 million and is part of the health care sector and health services industry. Shares are up 131.63% year-to-date as of the close of trading on Thursday.

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible products in the United States and internationally. The company has a P/E ratio of 149.4. Currently, there is 1 analyst who rates iRadimed a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IRMD - FREE

TheStreet Quant Ratings rates iRadimed as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the stock itself is trading at a premium valuation. Get the full iRadimed Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PMC-Sierra (PMCS) - FREE Research Report

Lang Gregory S, who is President and CEO at PMC-Sierra, sold 292,006 shares at $11.86 on Dec. 10, 2015. Following this transaction, the President and CEO owned 251,983 shares meaning that the stake was reduced by 53.68% with the 292,006-share transaction.

The shares most recently traded at $11.75, down $0.11, or 0.94% since the insider transaction. Historical insider transactions for PMC-Sierra go as follows:

  • 4-Week # shares sold: 279,261
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 279,261
  • 24-Week # shares bought: 15,000
  • 24-Week # shares sold: 279,727

The average volume for PMC-Sierra has been 9.0 million shares per day over the past 30 days. PMC-Sierra has a market cap of $2.3 billion and is part of the technology sector and electronics industry. Shares are up 28.82% year-to-date as of the close of trading on Thursday.

PMC-Sierra, Inc. designs, develops, markets, and supports semiconductor solutions for communications network infrastructure equipment worldwide. Its semiconductor devices enable networking equipment primarily in three markets, including storage, optical, and mobile networks. The company has a P/E ratio of 590.5. Currently, there are no analysts who rate PMC-Sierra a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PMCS - FREE

TheStreet Quant Ratings rates PMC-Sierra as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full PMC-Sierra Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ExamWorks Group (EXAM) - FREE Research Report

Presby J Thomas, who is Director at ExamWorks Group, bought 4,000 shares at $26.90 on Dec. 10, 2015. Following this transaction, the Director owned 71,886 shares meaning that the stake was boosted by 5.89% with the 4,000-share transaction.

The shares most recently traded at $27.15, up $0.25, or 0.92% since the insider transaction. Historical insider transactions for ExamWorks Group go as follows:

  • 4-Week # shares sold: 247,217
  • 12-Week # shares sold: 247,217
  • 24-Week # shares bought: 13,500
  • 24-Week # shares sold: 247,217

The average volume for ExamWorks Group has been 400,600 shares per day over the past 30 days. ExamWorks Group has a market cap of $1.1 billion and is part of the financial sector and insurance industry. Shares are down 34.79% year-to-date as of the close of trading on Thursday.

ExamWorks Group, Inc., together with its subsidiaries, provides independent medical examinations (IMEs), peer and bill reviews, Medicare compliance, and other related services in the United States, Canada, the United Kingdom, and Australia. The company has a P/E ratio of 221.6. Currently, there are 3 analysts who rate ExamWorks Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXAM - FREE

TheStreet Quant Ratings rates ExamWorks Group as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and poor profit margins. Get the full ExamWorks Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

The Final Barrier for One Last Bull Market High

The Final Barrier for One Last Bull Market High

Wednesday Wrap-Up: Roku Rebounds, Tesla Ships

Wednesday Wrap-Up: Roku Rebounds, Tesla Ships

A Tale of 2 Headquarters: New York City Divided by Amazon Debate

A Tale of 2 Headquarters: New York City Divided by Amazon Debate

Market Movers: December FOMC Meeting

Market Movers: December FOMC Meeting

Government Shutdown Won't Hurt Stocks Much, History Says

Government Shutdown Won't Hurt Stocks Much, History Says